Eupraxia Pharmaceuticals (EPRX) Institutional Ownership $5.32 -0.15 (-2.82%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Eupraxia Pharmaceuticals (NASDAQ:EPRX)Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$1.28MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$2.15M Get EPRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Eupraxia Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data EPRX Institutional Buying and Selling by Quarter Eupraxia Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Bank of America Corp DE12,559$72K0.0%+402.4%0.035% 8/13/2025 Quadrature Capital Ltd10,700$61K0.0%N/A0.030% 8/13/2025 Scotia Capital Inc.1,291,989$6.98M0.0%-16.8%3.593% 8/12/2025 JPMorgan Chase & Co.18,717$108K0.0%+593.2%0.052% 8/11/2025 TD Waterhouse Canada Inc.9,600$56K0.0%-90.9%0.027% 8/5/2025 Bank of Montreal Can37,250$215K0.0%-28.7%0.104% 7/31/2025 Ingalls & Snyder LLC37,200$214K0.0%N/A0.103% 5/15/2025Royal Bank of Canada342,828$1.13M0.0%+21.1%0.956% 5/9/2025Scotia Capital Inc.1,552,679$5.07M0.0%+11.6%4.331% 2/17/2025Millennium Management LLC10,000$31K0.0%N/A0.028% 2/13/2025Scotia Capital Inc.1,391,719$4.26M0.0%-0.3%3.907% 2/13/2025Raymond James Financial Inc.11,613$37K0.0%N/A0.033% 2/13/2025Bank of Montreal Can56,750$178K0.0%+15.2%0.159% 2/6/2025Raymond James Financial Inc.11,613$37K0.0%N/A0.033% 7/17/2024180 Wealth Advisors LLC13,000$34K0.0%N/A0.048% (Data available from 1/1/2016 forward) EPRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of EPRX shares? During the previous two years, 11 institutional investors and hedge funds held shares of Eupraxia Pharmaceuticals. The most heavily invested institutionals were Scotia Capital Inc. ($6.98M), Royal Bank of Canada ($1.13M), Bank of Montreal Can ($215K), Ingalls & Snyder LLC ($214K), JPMorgan Chase & Co. ($108K), Bank of America Corp DE ($72K), and Quadrature Capital Ltd ($61K).Learn more on Eupraxia Pharmaceuticals' institutional investors. Which institutional investors have been buying Eupraxia Pharmaceuticals' stock? Of the 10 institutional investors that purchased Eupraxia Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Scotia Capital Inc. ($160.96K), Royal Bank of Canada ($59.68K), Ingalls & Snyder LLC ($37.20K), Raymond James Financial Inc. ($23.23K), JPMorgan Chase & Co. ($16.02K), 180 Wealth Advisors LLC ($13K), and Quadrature Capital Ltd ($10.70K). How much institutional buying is happening at Eupraxia Pharmaceuticals? Institutional investors have bought a total of 335,345 shares in the last 24 months. This purchase volume represents approximately $1.28M in transactions. Which of Eupraxia Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Eupraxia Pharmaceuticals stock in the last 24 months: Scotia Capital Inc. ($265.25K), TD Waterhouse Canada Inc. ($95.39K), and Bank of Montreal Can ($15K). How much institutional selling is happening at Eupraxia Pharmaceuticals? Institutional investors have sold a total of 375,638 shares in the last 24 months. This volume of shares sold represents approximately $2.15M in transactions. Related Companies Niagen Bioscience Institutional Ownership Day One Biopharmaceuticals Institutional Ownership Vir Biotechnology Institutional Ownership Arbutus Biopharma Institutional Ownership Valneva Institutional Ownership Tango Therapeutics Institutional Ownership BGM Group Institutional Ownership Kura Oncology Institutional Ownership GH Research Institutional Ownership Nurix Therapeutics Institutional Ownership This page (NASDAQ:EPRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
